About Medicaps Limited
Data last updated:
Medicaps Limited is a public limited company based in Indore, Madhya Pradesh, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 August 1983 and has been in existence for over 43 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L70100MP1983PLC002231. Its GSTIN is 23AABCM1905G1Z1 (Madhya Pradesh). Its shares are listed on BSE: 523144.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.47 Cr. It was formerly known as Medicaps Pvt Limited. It is led by directors including Alok K Garg (Managing Director) and Ramesh Chandra Mittal.
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Indore, Madhya Pradesh.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹12.45 Cr, a decline of 51.1% compared to the previous year. For the same year it recorded a net loss of ₹10.73 Cr (net margin -86.2%) and EBITDA of -₹9.4 Cr (EBITDA margin -75.5%). The net worth stands at ₹111.61 Cr (down 8% YoY). Total assets are valued at ₹112.35 Cr (down 7.8% YoY).
The company has about 2 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Medi-Caps. As per MCA filings, the company has open charges of ₹20 Lakh and satisfied charges of ₹2.22 Cr on record. Court records list 22 cases involving the company, including 16 filed by the company and 5 filed against it; 10 cases are pending. The company has 23 deals on record (23 market trades); the latest was in January 2025. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Honest Bio Vet Private Limited with revenue of ₹28.44 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicaps.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address201 Pushpratna Paradise, 9/5 New Palasiya, Indore, Madhya Pradesh, India – 452001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Medicaps Limited
The main business activity of Medicaps is real estate. In detail, this covers real estate activities with own or leased property.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| L | Real Estate | L1 | Real estate activities with own or leased property | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Medicaps Limited FY 2025-26 filings available
Medicaps Limited reported revenue of ₹12.45 Cr (down 51.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 12.45 | 25.48 | 27.35 | 49.37 | 69.87 | 57.42 | 43.05 |
| Revenue growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| EBITDA | (9.40) | (1.81) | 0.01 | 5.08 | 10.07 | 10.86 | (6.77) |
| EBITDA margin | -75.5% | -7.1% | +0.0% | +10.3% | +14.4% | +18.9% | -15.7% |
| Profit before tax | (3.02) | (0.85) | (1.24) | 4.81 | 10.10 | 11.13 | (5.85) |
| Net profit | (10.73) | (2.36) | (2.43) | 1.22 | 9.62 | 11.26 | (6.28) |
| Net profit margin | -86.2% | -9.3% | -8.9% | +2.5% | +13.8% | +19.6% | -14.6% |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Balance sheet | |||||||
| Total assets | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Net worth | 112 | 121 | 121 | 119 | 116 | 105 | 90.95 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Cash & bank | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Net working capital | 20.90 | 21.64 | 24.61 | 28.22 | 26.53 | 17.11 | 11.31 |
| Cash flow | |||||||
| Cash from operations | (7.02) | 5.07 | 6.94 | (6.08) | 7.02 | 15.32 | 4.63 |
| Cash from investing | 7.11 | (4.98) | (7.73) | (2.56) | (4.08) | (9.70) | (5.80) |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79 | 3.45 | 4.30 | 2.02 | 2.69 | 6.97 | 4.02 | 8.29 |
| Revenue growth (YoY) | +3.7% | -50.5% | +7.0% | -75.6% | -56.6% | - | - | - |
| Other income | 0.05 | 5.59 | 0.76 | 1.53 | 0.33 | 2.14 | 0.16 | 0.29 |
| EBITDA | (1.83) | (2.06) | (1.06) | (2.91) | (3.37) | (0.22) | (1.78) | 0.45 |
| EBITDA margin | -67.3% | -60.2% | -24.7% | -144.8% | -125.7% | -3.2% | -44.4% | +5.4% |
| Depreciation | 0.45 | 0.50 | 0.44 | 0.44 | 0.44 | 0.44 | 0.43 | 0.43 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (2.23) | 3.03 | (0.74) | (1.82) | (3.49) | 1.46 | (2.05) | 0.31 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Net profit | (2.23) | 3.04 | (0.77) | (1.82) | (3.49) | 1.73 | (2.05) | 0.31 |
| EPS (₹) | (1.79) | 2.44 | (0.61) | (1.46) | (2.80) | 1.38 | (1.64) | 0.25 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.31 | 2.42 | 7.17 | 0.10 | 0.00 | 0.00 | 10.91 |
| Revenue growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| EBITDA | (0.50) | (0.10) | 4.84 | (0.40) | (0.56) | (0.12) | (9.08) |
| EBITDA margin | -21.7% | -4.1% | +67.5% | -400.0% | - | - | -83.2% |
| Profit before tax | (0.11) | 0.30 | 4.83 | 0.15 | (0.02) | (0.12) | (8.33) |
| Net profit | (0.61) | 0.19 | 3.77 | (0.49) | (0.49) | 0.01 | (8.68) |
| Net profit margin | -26.4% | +7.9% | +52.6% | -490.0% | - | - | -79.6% |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Balance sheet | |||||||
| Total assets | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Net worth | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 60.97 | 59.85 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Cash & bank | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Net working capital | 8.60 | 8.65 | 9.51 | 7.06 | 5.23 | 3.84 | 4.75 |
| Cash flow | |||||||
| Cash from operations | (0.47) | 1.85 | 3.09 | (2.60) | (0.95) | 2.24 | (0.92) |
| Cash from investing | 0.42 | (1.85) | (3.09) | 1.85 | 1.01 | (2.19) | (0.40) |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.53 | 0.77 | 1.00 | 0.00 | 0.89 | 0.26 | 0.98 |
| Revenue growth (YoY) | - | -40.5% | +196.2% | +2.0% | -100.0% | - | - | - |
| Other income | 0.00 | 0.08 | 0.17 | 0.01 | 0.31 | 0.27 | 0.09 | 0.10 |
| Total expenses | 0.65 | 0.88 | 0.59 | 0.68 | 0.67 | 0.68 | 0.57 | 0.59 |
| EBITDA | (0.55) | (0.35) | 0.18 | 0.32 | (0.67) | 0.21 | (0.31) | 0.39 |
| EBITDA margin | -1375.0% | -68.6% | +23.4% | +32.0% | - | +23.9% | -124.0% | +40.6% |
| Depreciation | 0.05 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.60) | (0.34) | 0.31 | 0.29 | (0.40) | 0.44 | (0.26) | 0.45 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79 | 3.45 | 4.30 | 2.02 | 2.69 | 6.97 | 4.02 | 8.29 |
| Revenue growth (YoY) | +3.7% | -50.5% | +7.0% | -75.6% | -56.6% | - | - | - |
| Other income | 0.05 | 5.59 | 0.76 | 1.53 | 0.33 | 2.14 | 0.16 | 0.29 |
| EBITDA | (1.83) | (2.06) | (1.06) | (2.91) | (3.37) | (0.22) | (1.78) | 0.45 |
| EBITDA margin | -67.3% | -60.2% | -24.7% | -144.8% | -125.7% | -3.2% | -44.4% | +5.4% |
| Depreciation | 0.45 | 0.50 | 0.44 | 0.44 | 0.44 | 0.44 | 0.43 | 0.43 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (2.23) | 3.03 | (0.74) | (1.82) | (3.49) | 1.46 | (2.05) | 0.31 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Net profit | (2.23) | 3.04 | (0.77) | (1.82) | (3.49) | 1.73 | (2.05) | 0.31 |
| EPS (₹) | (1.79) | 2.44 | (0.61) | (1.46) | (2.80) | 1.38 | (1.64) | 0.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.45 | 25.48 | 27.35 | 49.37 | 69.87 | 57.42 | 43.05 |
| Revenue growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| Other income | 8.21 | 2.73 | 0.48 | 1.60 | 1.95 | 1.89 | 2.87 |
| Total expenses | 21.85 | 27.29 | 27.34 | 44.29 | 59.80 | 46.56 | 49.82 |
| Employee cost | 5.97 | 5.81 | 5.21 | 5.65 | 5.62 | 4.96 | 10.70 |
| EBITDA | (9.40) | (1.81) | 0.01 | 5.08 | 10.07 | 10.86 | (6.77) |
| EBITDA margin | -75.5% | -7.1% | +0.0% | +10.3% | +14.4% | +18.9% | -15.7% |
| Depreciation | 1.81 | 1.72 | 1.69 | 1.74 | 1.81 | 1.52 | 1.83 |
| Interest | 0.02 | 0.05 | 0.04 | 0.13 | 0.11 | 0.10 | 0.12 |
| Profit before tax | (3.02) | (0.85) | (1.24) | 4.81 | 10.10 | 11.13 | (5.85) |
| Tax | 0.02 | (0.27) | 1.00 | 3.06 | 0.01 | (0.01) | 0.01 |
| Net profit | (10.73) | (2.36) | (2.43) | 1.22 | 9.62 | 11.26 | (6.28) |
| Net profit margin | -86.2% | -9.3% | -8.9% | +2.5% | +13.8% | +19.6% | -14.6% |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves & surplus | 99.14 | 109 | 109 | 106 | 104 | 92.24 | 78.48 |
| Shareholders' funds (net worth) | 112 | 121 | 121 | 119 | 116 | 105 | 90.95 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total liabilities | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Assets | |||||||
| Gross block | 93.16 | 92.45 | 92.51 | 91.09 | 92.53 | 90.28 | 88.07 |
| Net block | 56.29 | 57.18 | 58.64 | 58.91 | 59.31 | 58.12 | 57.29 |
| Capital work in progress | 0.00 | 0.08 | 0.00 | 0.00 | 0.24 | 0.54 | 0.97 |
| Investments | 34.82 | 43.04 | 38.38 | 32.07 | 30.67 | 29.41 | 21.97 |
| Inventories | 2.94 | 3.20 | 5.74 | 7.07 | 11.85 | 6.71 | 5.45 |
| Sundry debtors | 6.92 | 8.79 | 10.82 | 8.46 | 10.07 | 6.39 | 4.41 |
| Cash & bank balances | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Loans & advances | 13.25 | 12.34 | 12.99 | 17.97 | 8.06 | 6.47 | 3.51 |
| Total current assets | 23.61 | 24.74 | 29.87 | 34.61 | 39.73 | 26.38 | 14.62 |
| Total current liabilities | 2.71 | 3.10 | 5.26 | 6.39 | 13.20 | 9.27 | 3.31 |
| Net working capital | 20.90 | 21.64 | 24.61 | 28.22 | 26.53 | 17.11 | 11.31 |
| Total assets | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 | 2.48 |
| Net cash from operating activities | (7.02) | 5.07 | 6.94 | (6.08) | 7.02 | 15.32 | 4.63 |
| Net cash from investing activities | 7.11 | (4.98) | (7.73) | (2.56) | (4.08) | (9.70) | (5.80) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Net change in cash | 0.09 | 0.09 | (0.79) | (8.64) | 2.95 | 5.56 | (1.23) |
| Closing cash | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| EBITDA growth | -419.3% | - | -99.8% | -49.6% | -7.3% | +260.4% | - |
| PBT growth | -255.3% | +31.5% | - | -52.4% | -9.3% | +9998.0% | - |
| Net income growth | -354.7% | +2.9% | -299.2% | -87.3% | -14.6% | +279.3% | - |
| Revenue CAGR (3Y) | -36.8% | -28.6% | -21.9% | +4.7% | +10.5% | +2.3% | -0.8% |
| EBITDA CAGR (3Y) | - | - | -90.3% | - | +28.7% | +71.1% | - |
| Profitability & leverage | |||||||
| Net income margin | -24.4% | -2.3% | -8.2% | +3.5% | +14.4% | +19.4% | -13.6% |
| Return on capital employed | -9.1% | -2.1% | -1.2% | +3.7% | +9.2% | +11.4% | -6.1% |
| Return on net worth | -9.2% | -1.9% | -2.0% | +1.1% | +9.1% | +11.4% | -6.3% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -0.18 | -1.42 | -2.38 | 3.89 | 1.33 | 1.07 | -1.40 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.13 | 0.28 | 0.30 | 0.54 | 0.76 | 0.64 | 0.51 |
| Inventory turnover | 4.06 | 5.70 | 4.27 | 5.22 | 7.53 | 9.44 | 5.50 |
| Debtors turnover | 1.58 | 2.60 | 2.84 | 5.33 | 8.49 | 10.63 | 5.22 |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 89.50 | 97.25 | 97.02 | 95.09 | 93.23 | 83.97 | 72.94 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.53 | 0.77 | 1.00 | 0.00 | 0.89 | 0.26 | 0.98 |
| Revenue growth (YoY) | - | -40.5% | +196.2% | +2.0% | -100.0% | - | - | - |
| Other income | 0.00 | 0.08 | 0.17 | 0.01 | 0.31 | 0.27 | 0.09 | 0.10 |
| Total expenses | 0.65 | 0.88 | 0.59 | 0.68 | 0.67 | 0.68 | 0.57 | 0.59 |
| EBITDA | (0.55) | (0.35) | 0.18 | 0.32 | (0.67) | 0.21 | (0.31) | 0.39 |
| EBITDA margin | -1375.0% | -68.6% | +23.4% | +32.0% | - | +23.9% | -124.0% | +40.6% |
| Depreciation | 0.05 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.60) | (0.34) | 0.31 | 0.29 | (0.40) | 0.44 | (0.26) | 0.45 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.31 | 2.42 | 7.17 | 0.10 | 0.00 | 0.00 | 10.91 |
| Revenue growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| Other income | 0.58 | 0.56 | 0.15 | 0.64 | 0.64 | 0.00 | 1.12 |
| Total expenses | 2.81 | 2.52 | 2.33 | 0.50 | 0.56 | 0.12 | 19.99 |
| Employee cost | 1.01 | 0.97 | 0.50 | 0.23 | 0.45 | 0.00 | 5.55 |
| EBITDA | (0.50) | (0.10) | 4.84 | (0.40) | (0.56) | (0.12) | (9.08) |
| EBITDA margin | -21.7% | -4.1% | +67.5% | -400.0% | - | - | -83.2% |
| Depreciation | 0.19 | 0.16 | 0.16 | 0.09 | 0.09 | 0.00 | 0.36 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Profit before tax | (0.11) | 0.30 | 4.83 | 0.15 | (0.02) | (0.12) | (8.33) |
| Tax | 0.02 | (0.27) | 0.94 | 0.00 | 0.01 | (0.01) | 0.01 |
| Net profit | (0.61) | 0.19 | 3.77 | (0.49) | (0.49) | 0.01 | (8.68) |
| Net profit margin | -26.4% | +7.9% | +52.6% | -490.0% | - | - | -79.6% |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves & surplus | 54.24 | 54.87 | 54.02 | 48.64 | 48.82 | 48.50 | 47.38 |
| Shareholders' funds (net worth) | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 60.97 | 59.85 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total liabilities | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Assets | |||||||
| Gross block | 17.82 | 17.71 | 18.03 | 16.99 | 19.99 | 21.13 | 21.65 |
| Net block | 3.31 | 3.18 | 3.34 | 2.46 | 2.77 | 3.25 | 3.63 |
| Capital work in progress | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 55.13 | 55.81 | 54.03 | 51.98 | 53.68 | 54.39 | 52.15 |
| Inventories | 0.02 | 0.03 | 0.03 | 0.00 | 0.00 | 0.05 | 0.53 |
| Sundry debtors | 2.95 | 3.66 | 4.65 | 2.24 | 2.24 | 2.41 | 2.66 |
| Cash & bank balances | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Loans & advances | 5.85 | 5.18 | 5.95 | 4.86 | 2.28 | 1.75 | 1.78 |
| Total current assets | 8.83 | 8.92 | 10.68 | 7.14 | 5.31 | 4.94 | 5.72 |
| Total current liabilities | 0.23 | 0.27 | 1.17 | 0.08 | 0.08 | 1.10 | 0.97 |
| Net working capital | 8.60 | 8.65 | 9.51 | 7.06 | 5.23 | 3.84 | 4.75 |
| Total assets | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 | 2.13 |
| Net cash from operating activities | (0.47) | 1.85 | 3.09 | (2.60) | (0.95) | 2.24 | (0.92) |
| Net cash from investing activities | 0.42 | (1.85) | (3.09) | 1.85 | 1.01 | (2.19) | (0.40) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Net change in cash | (0.05) | 0.01 | 0.00 | (0.75) | 0.06 | (0.02) | (1.38) |
| Closing cash | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| EBITDA growth | -400.0% | -102.1% | +1310.0% | +28.6% | -366.7% | +98.7% | - |
| PBT growth | - | -93.8% | +3120.0% | +9998.0% | +83.3% | +98.6% | - |
| Net income growth | -421.1% | -95.0% | +869.4% | 0.0% | -5000.0% | +100.1% | - |
| Revenue CAGR (3Y) | +184.8% | - | - | -79.1% | -100.0% | -100.0% | -21.7% |
| EBITDA CAGR (3Y) | +7.7% | -43.7% | - | -64.7% | +141.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -5.6% | +23.6% | +54.3% | +150.0% | - | - | -76.4% |
| Return on capital employed | -0.9% | -0.1% | +7.6% | -0.6% | -0.9% | 0.0% | -12.9% |
| Return on net worth | -0.9% | +0.3% | +6.1% | -0.8% | -0.8% | +0.0% | -13.1% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | -1.54 | 0.00 | -0.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.13 | 0.14 | 0.41 | 0.01 | 0.00 | 0.00 | 0.58 |
| Inventory turnover | 92.40 | 80.67 | 478.00 | 0.00 | 0.00 | 0.00 | 3.45 |
| Debtors turnover | 0.70 | 0.58 | 2.08 | 0.04 | 0.00 | 0.00 | 2.90 |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 53.50 | 54.00 | 53.32 | 49.00 | 49.15 | 48.89 | 47.99 |
Peer Comparison of Medicaps Limited
Medicaps Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Honest Bio Vet Private Limited | ₹28.44 Cr (FY 2025) | •••• | •••• | 32.0% | •••• | Gujarat, India |
| Alicon Pharmaceutical Private Limited | ₹28.34 Cr (FY 2024) | •••• | •••• | 28.0% | •••• | Palghar, Maharashtra, India |
| Eisen Pharmaceutical Company (Private) Limited | ₹28.28 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Pune, Maharashtra, India |
| Astra-Idl Limited | ₹28.28 Cr (FY 2024) | •••• | •••• | 120.0% | •••• | Mumbai, Maharashtra, India |
| Kamlaamrut Pharmaceutical LLP | ₹28.26 Cr (FY 2023) | •••• | •••• | 34.0% | •••• | Kalol, Gujarat, India |
| Indus Pharma Private Limited | ₹28.11 Cr (FY 2023) | •••• | •••• | -58.0% | •••• | New Delhi, Delhi, India |
| Novita Healthcare Private Limited | ₹28.02 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Mumbai, Maharashtra, India |
| Inven Pharmaceuticals Private Limited | ₹27.99 Cr (FY 2025) | •••• | •••• | -6.0% | •••• | Indore, Madhya Pradesh, India |
| Aashka Formulation Private Limited | ₹27.95 Cr (FY 2022) | •••• | •••• | 904.0% | •••• | Kalol, Gujarat, India |
| Danashmand Organic Private Limited | ₹27.92 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Mumbai, Maharashtra, India |
| Medicaps Limited this company | ₹12.45 Cr (FY 2026) | •••• | •••• | -51.1% | •••• | Indore, Madhya Pradesh, India |
Peers are the five companies nearest above and the five nearest below Medicaps by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Medicaps Limited
Medicaps Limited is audited by Rawka & Associate for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Rawka & Associate | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Medicaps Limited
Medicaps has 6 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Alok K Garg Also directs: Medgel Private Limited | Managing Director | 01 Apr 2007 | 19 Years 6 Months | Current |
| Ramesh Chandra Mittal | Director | 06 Aug 1983 | 43 Years 2 Months | Current |
| Ashok Agrawal Omprakash Also directs: Medgel Private Limited | Director | 25 Jul 2017 | 9 Years 2 Months | Current |
| Kusum Mittal | Director | 04 May 1991 | 35 Years 5 Months | Current |
| Dharmendra Solanki | Director | 05 Feb 2021 | 5 Years 8 Months | Current |
| Gajendra Singh | Director | 11 Aug 2023 | 3 Years 1 Months | Current |
Shareholding Pattern of Medicaps Limited
Shareholding for the quarter ended Sep 2026: promoters hold 51.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 48.60%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 51.40% | 51.40% | 50.80% | 50.80% |
| Public | 48.60% | 48.60% | 49.20% | 49.20% |
Charges & Borrowings of Medicaps Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Mar 1992 | Bank of Baroda | ₹3 Lakh | Open |
| 05 Oct 1990 | Bank of Baroda | ₹10 Lakh | Open |
| 24 Jul 1986 | Bank of Baroda | ₹7 Lakh | Open |
| 03 Mar 2018 | Axis Bank Limited | ₹17.46 Lakh | Satisfied |
| 22 Jan 1996 | I.D.B.I. Bank Ltd. | ₹1.15 Cr | Satisfied |
Total charge records: 6 View all charges
Deals & Funding of Medicaps Limited
Medicaps Limited has 23 deals on record (23 market trades); the latest was in January 2025.
Deals on record (5 of 23)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2025 | Market trade | ₹71.8 Lakh | Buyer: an individual |
| Apr 2024 | Market trade | ₹43.7 Lakh | Buyer: an individual Seller: an individual |
| Mar 2023 | Market trade | ₹47.9 Lakh | Buyer: an individual Seller: an individual |
| Jun 2021 | Market trade | ₹42.7 Lakh | Seller: an individual |
| Dec 2015 | Market trade | ₹53.8 Lakh | Buyer: Yuga Stocks & Commodities Private Limited Seller: Yuga Stocks & Commodities Private Limited |
Full deal history
All 23 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Medicaps Limited
Medicaps Limited has 22 court cases on record: 16 filed by Medicaps, 5 filed against it, 1 where it is another party. 10 cases are pending and 12 are disposed. Status as checked between 30 Sep 2026 and 05 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 21 | 4 | 10 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 22)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against Beloorbayir Biotech Limited | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against Beloorbayir Biotech Limited | Pending |
| District court, Indore, Madhya Pradesh | Court case (RCS B) | Filed against the company by Indusind Bank Ltd. | Disposed |
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against Niss Lboratories Ltd | Pending |
| District court, Dhar, Madhya Pradesh | Court case (RCS A) | Filed by the company against an individual | Pending |
Full case history
All 22 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Associated Brands with Medicaps Limited
Medicaps operates one associated brand: Medi-Caps. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of empty gelatin capsules | medicaps.com |
Employees and EPFO Compliance at Medicaps Limited
Medicaps Limited has a workforce of 2 employees as of Apr 05, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Medicaps Limited
Medicaps has 1 subsidiary company. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Medgel Private Limited | U24239MP2007PTC019204 | - |
Showing major subsidiaries. Total: 1.
CIN History of Medicaps Limited
Medicaps has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L70100MP1983PLC002231, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L70100MP1983PLC002231 | Current |
| U24232MP1983PLC002231 | Previous |
| L24232MP1983PLC002231 | Previous |
Recent Activity on Medicaps Limited
Medicaps Limited has 30 board changes on record since 1983: 18 appointments and 12 cessations. The latest: Pramod Fatehpuria ceased to be Director on 28 May 2024.
31 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Medicaps Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Medicaps Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Medicaps Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Medicaps Limited
Medicaps has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AABCM1905G1Z1 | Madhya Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Medicaps Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medicaps Limited
Medicaps is an active public limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 August 1983 (43+ years old) and is registered under CIN L70100MP1983PLC002231. Listed on BSE: 523144.
Medicaps reported revenue of ₹12.45 Cr for FY 2025-26 (down 51.1% YoY) based on consolidated financials.
Medicaps has 6 current directors:
- Alok K Garg - Managing Director
- Ramesh Chandra Mittal - Director
- Ashok Agrawal Omprakash - Director
- Kusum Mittal - Director
- Dharmendra Solanki - Director
- Gajendra Singh - Director
The GSTIN of Medicaps is 23AABCM1905G1Z1, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Medicaps is L70100MP1983PLC002231. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Medicaps is listed on BSE with code 523144.
Medicaps has 22 court cases on record: 16 filed by the company and 5 filed against it. 10 are pending. Most are in the district courts.
Medicaps was incorporated on 06 August 1983, making it 43+ years old. It is registered with the Registrar of Companies, Gwalior.
Medicaps has 23 deals on record (23 market trades); the latest was in January 2025.
The peers of Medicaps by revenue are Honest Bio Vet Private Limited, Alicon Pharmaceutical Private Limited, Eisen Pharmaceutical Company (Private) Limited, Astra-Idl Limited, Kamlaamrut Pharmaceutical LLP and 5 more, all in the Pharma industry (Formulations).
Pramod Fatehpuria ceased to be Director on 28 May 2024. Gajendra Singh was appointed as Director on 11 Aug 2023. Akshit Garg ceased to be Director on 21 Jul 2023. Medicaps has 30 board changes on record in total.